0000880771-17-000091.txt : 20170606 0000880771-17-000091.hdr.sgml : 20170606 20170606183741 ACCESSION NUMBER: 0000880771-17-000091 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170602 FILED AS OF DATE: 20170606 DATE AS OF CHANGE: 20170606 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SCICLONE PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000880771 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943116852 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 950 TOWER LANE STREET 2: SUITE 900 CITY: FOSTER CITY STATE: CA ZIP: 94404-2125 BUSINESS PHONE: 650-358-3456 MAIL ADDRESS: STREET 1: 950 TOWER LANE STREET 2: SUITE 900 CITY: FOSTER CITY STATE: CA ZIP: 94404-2125 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Blobel Friedhelm CENTRAL INDEX KEY: 0001363213 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19825 FILM NUMBER: 17895262 MAIL ADDRESS: STREET 1: 950 TOWER LANE, SUITE 900 CITY: FOSTER CITY STATE: CA ZIP: 94404 4 1 certent-form4.xml PRIMARY DOCUMENT X0306 4 2017-06-02 0000880771 SCICLONE PHARMACEUTICALS INC SCLN 0001363213 Blobel Friedhelm 950 TOWER LANE, SUITE 900 FOSTER CITY CA 94404 1 1 0 0 President & CEO Common Stock 2017-06-02 4 M 0 4800 3.55 A 98099 D Common Stock 2017-06-02 4 S 0 4800 10 D 93299 D Common Stock 2017-06-06 4 M 0 5500 3.55 A 98799 D Common Stock 2017-06-06 4 S 0 5500 10.00 D 93299 D Non-Qualified Stock Option (right to buy) 3.55 2017-06-02 4 M 0 4800 0 D 2020-03-05 Common Stock 4800 142810 D Non-Qualified Stock Option (right to buy) 3.55 2017-06-06 4 M 0 5500 0 D 2020-03-05 Common Stock 5500 137310 D The reported sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 18, 2016. Includes 773 shares purchased under the Issuer's Employee Purchase Plan on May 31, 2017. Granted under the Issuer's 2005 Equity Incentive Plan. 25% of each shares vest one year from the date of grant, of March 5, 2010, and 2.0833% vests each month thereafter, provided that Reporting Person continues to be employed by the Issuer. /s/ Friedhelm Blobel, Ph.D. 2017-06-06